<DOC>
	<DOC>NCT00073749</DOC>
	<brief_summary>To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).</brief_summary>
	<brief_title>Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<criteria>Subjects who have been previously diagnosed with CD22positive, Bcell NHL, according to WHO classification, which has progressed after at least 2 prior therapies of probable clinical benefit At the expanded cohort, part 2 of the study, subjects must have one of the following: Follicular lymphoma previously treated with at least one dose of rituximab, but have not received radioimmunotherapy Diffuse large Bcell lymphoma Age 18 years or older Candidate for potentially curative therapies in the opinion of the investigator Chronic lymphocytic leukemia Burkitt's lymphoma, primary effusion lymphoma, and precursor Bcell lymphoblastic lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>B-Cell</keyword>
	<keyword>Non-Hodgkin's</keyword>
	<keyword>Lymphoma</keyword>
</DOC>